Get to know our clinical trials
Trial of Elranatamab as a single agent for the treatment of relapsed or refractory myeloma in patients previously exposed to three classes of drugs.
THE OBJECTIVE OF THIS STUDY IS TO ASSESS THE EFFICACY OF THE INVESTIGATIONAL DRUG ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 3 PRIOR ANTI-MYELOMA DRUGS.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- Code EudraCT: 2023-504273-21-00
- Protocol number: GEM-RANTAB
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.